Asparaginase

Revision as of 19:32, 27 September 2011 by WikiBot (talk | contribs) (Protected "Asparaginase": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Asparaginase
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)
ATC code
Pharmacokinetic data
Elimination half-life8-30 hrs
Identifiers
CAS Number
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC1377H2208N382O442S17
Molar mass31731.9 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Template:Editor help

Asparaginase (EC 3.5.1.1) is an enzyme that catalyzes the hydrolysis of asparagine to aspartic acid. It is also marketed under the brand names Elspar®, Oncaspar, and Erwinase to treat acute lymphoblastic leukemia (ALL) and is also used in some mast cell tumor protocols. [1] Unlike other chemotherapy agents, it can be given as an intramuscular, subcutaneous, or intravenous injection without fear of tissue irritation.

Mechanism of action

The rationale behind asparaginase is that it takes advantage of the fact that ALL leukemic cells are unable to synthesize the non-essential amino acid asparagine whereas normal cells are able to make their own asparagine. These leukemic cells depend on circulating asparagine. Asparaginase however catalyzes the conversion of L-asparagine to aspartic acid and ammonia. This deprives the leukemic cell of circulating asparagine.

Side effects

The main side effect is an allergic or hypersensitivity reaction. Asparaginase has also been associated with pancreatitis. Additionally, it can also be associated with a coagulopathy as it decreases protein synthesis, including synthesis of coagulation factors and anticoagulant factor, leading to bleeding or thrombotic events such as stroke.

References

  1. Appel IM, van Kessel-Bakvis C, Stigter R, Pieters R (2007). "Influence of two different regimens of concomitant treatment with asparaginase and dexamethasone on hemostasis in childhood acute lymphoblastic leukemia". doi:10.1038/sj.leu.2404793. PMID 17554375.

External links

[2] THE PET PHARMACY By Wendy C. Brooks, DVM, DipABVP; Educational Director, VeterinaryPartner.com

Template:Pharma-stub

de:Asparaginase


Template:WikiDoc Sources